Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BTIG Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $14

Author: Benzinga Newsdesk | May 09, 2024 03:10pm
BTIG analyst Robert Hazlett maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the price target from $7 to $14.

Posted In: RANI

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist